Skip to content
DataLookout
Menu

NCT06651281

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary endpoint(s) modified, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 27 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 5 words
  2. Notable Primary endpoint(s) modified
    • Primary endpoint(s) modified
  3. Notable Primary endpoints: 2 to 4
    • Secondary endpoints shortened, about 63 words
  4. Notable Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised at 3 of 37 sites
  5. Minor Site contacts updated at 1 of 37 sitesv25
Show 21 earlier versionsHide 21 earlier versions
  1. Minor Study sites revised (37)v24
  2. Minor Site details revised at 1 of 37 sitesv23
  3. Minor Site contacts updated at 1 of 37 sitesv22
  4. Minor Site contacts updated at 2 of 37 sitesv21
  5. Minor Study sites: 38 to 37v20
  6. Minor Site contacts updated at 3 of 38 sitesv19
  7. Minor Study sites: 37 to 38v18
  8. Minor Study sites: 34 to 37v17
  9. Minor Study sites: 21 to 34v16
  10. Minor Study sites: 15 to 21v15
  11. Minor Study sites: 13 to 15v14
  12. Minor Study sites: 11 to 13v13
  13. Minor Study sites: 10 to 11v12
  14. Minor Study sites: 8 to 10v11
  15. Minor Study sites: 4 to 8v10
  16. Minor Study sites: 3 to 4v9
  17. Minor Study sites: 2 to 3v8
  18. Minor Enrollment target: 1349 to 1380
    • Study sites: 1 to 2
    v7
  19. Minor Start date changed from estimate of Dec 18, 2024 to Nov 25, 2024v6
  20. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v4
  21. Minor Secondary endpoints: details revised at 1 of 4 entriesv3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 378 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 364 weeks

Arms and interventions

Group 1: Low Dose UnblindedExperimental

Participants receive a low dose subcutaneous (SC) tulisokibart regimen.

Group 2: High Dose UnblindedExperimental

Participants receive a high dose SC tulisokibart regimen.

Group 3: High Dose BlindedExperimental

Participants receive a blinded high dose SC tulisokibart regimen.

Group 4: Low Dose BlindedExperimental

Participants receive a blinded low dose SC tulisokibart regimen.

Drugs: Tulisokibart, Placebo to tulisokibart

Sites

37 sites in 7 countries

Poland 14, United States 12, France 4, Czechia 2, Hungary 2, United Kingdom 2, Georgia 1